One approach to exploit the metabolic vulnerability of tumour cells has been through the development of AZD3965, an orally bioavailable inhibitor of monocarboxylate transporter 1 (MCT1), which is currently under Phase I clinical investigation (NCT01791595). Here, SLC16A1 is linked to neoplasm.